26.7 C
Vientiane
Monday, October 6, 2025
spot_img
Home Blog Page 904

Webull Announces Redemption of Incentive Warrants

ST. PETERSBURG, Fla., May 29, 2025 /PRNewswire/ — Webull Corporation (Nasdaq: BULL) (“Webull” or the “Company”), the owner of the Webull online investment platform, announced today that it has delivered a notice of redemption to redeem on June 30, 2025 (the “Redemption Date”) all of its outstanding incentive warrants (the “Incentive Warrants”; Nasdaq: BULLZ), which are exercisable for the Company’s Class A ordinary shares, par value $0.00001 per share (the “Class A Ordinary Shares”) at an exercise price of $10.00 per share and which were issued in connection with the closing of the Company’s business combination under the Warrant Agreement, dated as of April 10, 2025 (the “Warrant Agreement”), by and between the Company and Continental Stock Transfer & Trust Company, as warrant agent (the “Warrant Agent”). Any Incentive Warrants that remain unexercised at 5:00 p.m., New York City time, on the Redemption Date will be void and no longer exercisable and their holders will have no rights with respect to those Incentive Warrants, except to receive a redemption price of $0.01 per Incentive Warrant they hold (the “Redemption Price”). At the direction of the Company and pursuant to the Warrant Agreement, the Warrant Agent has delivered a notice of redemption to each registered holder of the outstanding Incentive Warrants.

Under the terms of the Warrant Agreement, the Company has the right to redeem all of the outstanding Incentive Warrants if the volume weighted average price of the Class A Ordinary Shares for the 30 trading-day period ending on the third trading day prior to the date on which the notice of redemption is given equals or exceeds $18.00 per Class A Ordinary Share. The volume weighted average price of the Class A Ordinary Shares for the 30 trading-day period ending on May 23, 2025, which is the third trading day prior to the date of the redemption notice, was greater than $18.00 per share.

The Incentive Warrants may be exercised by the holders thereof before 5:00 p.m. New York City time on the Redemption Date to purchase fully paid and non-assessable shares of Class A Ordinary Shares underlying such Incentive Warrants, at the exercise price of $10.00 per share. None of the Company, its board of directors or employees has made or is making any representation or recommendation to any holder of the Incentive Warrants as to whether to exercise or refrain from exercising any Incentive Warrants.

A prospectus covering the Class A Ordinary Shares issuable upon the exercise of the Incentive Warrants is included in a Registration Statement on Form F-1 (Registration No. 333-286880) (the “Registration Statement”), filed with, and declared effective by, the U.S. Securities and Exchange Commission (the “SEC”).

Questions concerning redemption or exercise of the Incentive Warrants can be directed to Continental Stock Transfer & Trust Company, 1 State Street, 30th Floor, New York, New York 10004, Attention: Compliance Department, telephone number (212) 509-4000.

No Offer or Solicitation

This press release shall not constitute an offer to sell or the solicitation of an offer to buy or of a decision to exercise or to redeem any securities of the Company, nor shall there be any sale of any securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Webull

Webull Corporation (NASDAQ: BULL) owns and operates Webull, a leading digital investment platform built on next-generation global infrastructure. Through its global network of licensed brokerages, Webull offers investment services in 14 markets across North America, Asia Pacific, Europe, and Latin America. Webull serves more than 24 million registered users globally, providing retail investors with 24/7 access to global financial markets. Users can put investment strategies to work by trading global stocks, ETFs, options, futures, and fractional shares through Webull’s trading platform, which seamlessly integrates market data and information, its user community, and investor education resources. Learn more at www.webullcorp.com. You may also access certain information on Webull and its securities on the website of the SEC at http://www.sec.gov, where Webull will, among others, be filing reports, such as Reports on Form 6-K and its Annual Report on Form 20-F. 

Cautionary Note Regarding Forward-Looking Statements

This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact contained in this press release or other statements of the Company, including statements related to the planned redemption of the Incentive Warrants, the issuance of shares upon exercise of the Incentive Warrants or the planned payment of the Redemption Price, are forward-looking statements. Some of these forward-looking statements can be identified by the use of forward-looking words, including “anticipate,” “expect,” “suggests,” “plan,” “believe,” “predict,” “potential,” “seek,” “future,” “propose,” “continue,” “intend,” “estimates,” “targets,” “projects,” “should,” “could,” “would,” “may,” “will,” “forecast” or the negatives of these terms or variations of them or similar terminology although not all forward-looking statements contain such terminology.

All forward-looking statements are based upon current estimates and forecasts and reflect the reasonable views, assumptions, expectations, and opinions of the Company and its management as of the date of this press release, and are therefore subject to a number of factors, risks and uncertainties, some of which are not currently known to the Company and its management and could cause actual results to differ materially from those expressed or implied by such forward-looking statements. Some of these factors include, but are not limited to: (1) the ability of the Company to capitalize on the anticipated benefits of the business combination, to grow and manage growth profitably, maintain relationships and deepen engagement with users, customers and suppliers, and retain its management and key employees; (2) the reliance of key functions of the Company’s business on third-parties and the risk that the Company’s platform and systems rely on software and applications that are highly technical and may contain undetected errors that could result in unexpected network interruptions, failures, security breaches, or computer virus attacks; (3) the risks associated with the Company’s global operations and continued global expansion, including, but not limited to, the risks related to complex or constantly evolving political or regulatory environments that may result in substantial costs or require adverse changes to the Company’s business practices; (4) the Company’s estimates of expenses and costs (including costs related to the business combination), of profitability or of other operational and financial metrics as well as the Company’s expectations regarding demand for and market acceptance of its products and service; (5) the Company’s reliance on trading related income, including payment for order flow (“PFOF”), and the risk of new regulation or bans on PFOF and similar practices; (6) the Company’s exposure to fluctuations in interest rates, rapidly changing interest rate environments, volatile prices of securities and trading volumes; (7) the Company’s reliance on a limited number of market makers and liquidity providers to generate a large portion of its revenues, and the negative impact of the loss of any of those market makers or liquidity providers; (8) the effects of competition in the Company’s industry and the Company’s need to constantly innovate and invest in new markets, products, technologies or services to retain, attract and deepen engagement with users; (9) changes in international trade policies and trade disputes that could result in tariffs, taxes or other protectionist measures adversely affecting our business; (10) risks related to general political, economic and business conditions globally and in jurisdictions where the Company operates; (11) risk of further actions taken by various government bodies in the United States that have made the Company the subject of inquiries and investigations relating to concerns about our connections to China; (12) the risk that the failure to protect customer data and privacy or to prevent security breaches relating to the Company’s platform could result in economic loss, damage to its reputation, deter customers from using its products and services, and expose it to legal penalties and liability; (13) risks related to the Company’s need as a regulated financial services company to develop and maintain effective compliance and risk management infrastructures as well as to maintain capital levels required by regulators and self-regulatory organizations; (14) the ability to meet, or continue to meet, stock exchange listing standards; (15) the possibility of adverse developments in pending or new litigation and regulatory investigations; (16) risks related to the Company’s securities and its status as a foreign private issuer and the fact that the information the Company is required to file with or furnish to the SEC may be less extensive and less timely compared to that required to be filed with the SEC by U.S. domestic issuers; (17) the effectiveness of the Registration Statement for resales or exercises of our warrants throughout the 30-day Redemption Period (as defined in the Warrant Agreement) as well as the risks related to the offer and resale of our securities, such as dilution from the issuance of additional Class A Ordinary Shares upon the exercise of warrants, and increased volatility, or significant declines, in the price of our securities based on increased trading activity and the perception that sales of our securities may occur; and (18) other risks and uncertainties that are more fully described in filings made, or to be made, by the Company with the SEC, including in the sections entitled “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” in the Company’s filings with the SEC. The foregoing list of factors is not exhaustive. Reported results should not be considered an indication of future performance. There may be additional risks that the Company and its management presently do not know about or that the Company and its management currently believe are immaterial that could also cause actual results to differ materially from those contained in the forward-looking statements. In light of these factors, risks and uncertainties, the forward-looking events and circumstances discussed in this press release may not occur, and any estimates, assumptions, expectations, forecasts, views or opinions set forth in this press release should be regarded as preliminary and for illustrative purposes only and accordingly, undue reliance should not be placed upon the forward-looking statements. The Company assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.

Webull Investor Relations
ir@webullcorp.com

Webull Media Relations
5W Public Relations
Nicholas Koulermos
Webull@5wpr.com
(212) 999-5585

First patient imaged in Phase III AMPLIFY trial with 64Cu-SAR-bisPSMA PET/CT

SYDNEY, May 29, 2025 /PRNewswire/ — Clarity Pharmaceuticals (ASX: CU6) (“Clarity” or “Company”), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with cancer, is pleased to announce that it has imaged the first patient in its registrational Phase III 64Cu-SAR-bisPSMA diagnostic trial in participants with biochemical recurrence (BCR) of prostate cancer, AMPLIFY (NCT06970847)[1], at XCancer in Omaha, Nebraska (NE).

Dr Luke Nordquist, Urologic Medical Oncologist, CEO, XCancer, commented, “We are thrilled to recruit the first participant in the AMPLIFY trial and to image them just over a week after study initiation. 64Cu-SAR-bisPSMA could become a best-in-class diagnostic prostate-specific membrane antigen (PSMA) agent, and we are honoured to be part of this registrational trial that intends to gather sufficient data for a New Drug Application (NDA) and a potential subsequent commercialisation of this next-generation product.

“We have already observed the potential benefits of 64Cu-SAR-bisPSMA based on data from earlier phase trials such as Clarity’s PROPELLER and COBRA studies and look forward to participating in the AMPLIFY trial, providing this optimised product to our patients in need of novel diagnostic solutions. The COBRA trial[2] that laid foundation for AMPLIFY in patients with BCR of prostate cancer showed that more lesions and more patients with a positive scan were identified on 64Cu-SAR-bisPSMA positron emission tomography (PET) compared to conventional scans and on next-day vs. same-day imaging. 64Cu-SAR-bisPSMA also allowed for the identification of lesions in the 2-mm range and was able to detect lesions at least 6 months earlier than the current standard-of-care (SOC) PSMA PET agents. The team at XCancer looks forward to further building on this evidence in the AMPLIFY trial as we progress towards our mutual goal of improving treatment outcomes for patients with cancer.”

Clarity’s Executive Chairperson, Dr Alan Taylor, commented, “We are excited to have imaged the first patient in the AMPLIFY trial and look forward to further progressing recruitment and opening clinical sites across the United States (US) and Australia, providing access to 64Cu-SAR-bisPSMA in both countries as part of this trial. We have built a robust supply of copper-64 with a wide network of product manufacturers in preparation for our two Phase III trials, AMPLIFY in BCR and CLARIFY[3] in pre-prostatectomy, and potential commercialisation. As such, we are ideally positioned to build on the clinical advantages of 64Cu-SAR-bisPSMA based on its higher lesion uptake and contrast, increased lesion detection rate compared to SOC imaging and flexible imaging schedule, enabled by its dual targeting (bisPSMA), proprietary chelator technology (sarcophagine, SAR) and copper-64 properties. We are also prepared to fully leverage the logistical and supply chain advantages associated with the optimal half-life of this isotope, in comparison to short-lived gallium-68 and fluorine-18, which allows 64Cu-SAR-bisPSMA to be made centrally in one location and shipped on-demand to any treatment facility in the country. This model enables better access and geographic distribution, meaning men with cancer could get an accurate and early diagnosis whether their location is a major city or regional area, as long as there is a PET camera on site.

“With prostate cancer prevalence increasing year after year, we look forward to overcoming limitations of the current-generation PSMA PET diagnostics, such as sensitivity and accessibility, making earlier and more accurate detection of recurrent disease a potential reality and bringing our optimised diagnostic to more men with this insidious disease around the world.”

About the AMPLIFY trial

AMPLIFY’s official title is “64Cu-SAR-bisPSMA Positron Emission Tomography: A Phase 3 Study of Participants with Biochemical Recurrence of Prostate Cancer” (NCT06970847)[1]. It is a non-randomised, single-arm, open-label, multi-centre, diagnostic clinical trial of 64Cu-SAR-bisPSMA PET in participants with rising or detectable prostate-specific antigen (PSA) after initial definitive treatment.

The aim of this trial is to investigate the ability of 64Cu-SAR-bisPSMA PET/computed tomography (CT) to detect recurrence of prostate cancer, with evaluation across 2 imaging timepoints, Day 1 (day of administration, same-day imaging) and Day 2 (approximately 24 hours post administration, next-day imaging).

The study will enroll approximately 220 participants at multiple clinical sites across the US and Australia. As a pivotal trial, the final study results are intended to provide sufficient evidence to support an application to the US Food and Drug Administration (FDA) for approval of 64Cu-SAR-bisPSMA as a new diagnostic imaging agent in BCR of prostate cancer.

About SAR-bisPSMA

SAR-bisPSMA derives its name from the word “bis”, which reflects a novel approach of connecting two PSMA-targeting agents to Clarity’s proprietary sarcophagine (SAR) technology that securely holds copper isotopes inside a cage-like structure, called a chelator. Unlike other commercially available chelators, the SAR technology prevents copper leakage into the body. SAR-bisPSMA is a Targeted Copper Theranostic (TCT) that can be used with isotopes of copper-64 (Cu-64 or 64Cu) for imaging and copper-67 (Cu-67 or 67Cu) for therapy.

Disclaimer

67Cu-SAR-bisPSMA and 64Cu-SAR-bisPSMA are unregistered products. The safety and efficacy of 67Cu-SAR-bisPSMA and 64Cu-SAR-bisPSMA have not been assessed by health authorities such as the US FDA or the Therapeutic Goods Administration (TGA). There is no guarantee that these products will become commercially available.

About Prostate Cancer

Prostate cancer is the second most common cancer diagnosed in men globally and the fifth leading cause of cancer death in men worldwide[4]. Prostate cancer is the second-leading causes of cancer death in American men. The American Cancer Institute estimates in 2025 there will be about 313,780 new cases of prostate cancer in the US and around 35,770 deaths from the disease[5].

About Clarity Pharmaceuticals

Clarity is a clinical stage radiopharmaceutical company focused on the treatment of serious diseases. The Company is a leader in innovative radiopharmaceuticals, developing Targeted Copper Theranostics based on its SAR Technology Platform for the treatment of cancers.

www.claritypharmaceuticals.com

For more information, please contact:

Clarity Pharmaceuticals
Dr Alan Taylor                                                  Catherine Strong
Executive Chairperson                                  Investor/Media Relations
ataylor@claritypharm.com                               c.strong@morrowsodali.com
                                                                         +61 406 759 268

References

1.     ClinicalTrials.gov Identifier: NCT06970847, https://clinicaltrials.gov/ct2/show/NCT06970847

2.     Nordquist et al. COBRA: Assessment of safety and efficacy of 64Cu-SAR-bisPSMA in patients with biochemical recurrence of prostate cancer following definitive therapy. EANM, 2024.

3.     ClinicalTrials.gov Identifier: NCT06056830, https://clinicaltrials.gov/study/NCT06056830

4.     Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries, https://acsjournals.onlinelibrary.wiley.com/doi/10.3322/caac.21660

5.     American Cancer Society: Key Statistics for Prostate Cancer, https://www.cancer.org/cancer/prostate-cancer/about/key-statistics.html

This announcement has been authorised for release by the Executive Chairperson.

Dx&Vx Accelerates Development of Universal COVID-19 Vaccine

  • Emerging as a next-generation vaccine amidst global resurgence of COVID-19
  • Expanding v arious pipelines other than universal COVID vaccine

SEOUL, South Korea, May 29, 2025 /PRNewswire/ — Bio-healthcare company Dx&Vx (DXVX) has officially announced the acceleration of its development program for a universal COVID-19 vaccine, following the recent acquisition of related technology. Designed to provide immunity against both current and future variants of the coronavirus, this next-generation vaccine is drawing global attention amid a new wave of COVID-19 cases worldwide.

Global health organizations, including the WHO, have raised concerns about rising COVID-19 cases in parts of Europe, Asia, and North America. These warnings have highlighted the urgent need for more robust and lasting immune solutions against evolving virus variants.

DXVX, a company led by COREE Group Chairman Chong-Yoon Lim, the eldest son of Hanmi Pharmaceutical Group’s founder, secured the universal vaccine technology late last year. The vaccine under development uses a virus-like particle (VLP) platform, which offers greater stability and ease of storage compared to mRNA vaccines. Theoretically, it has the potential to prevent infections caused by all known and future COVID-19 variants.

Currently, DXVX is advancing through the regulatory procedures necessary to initiate Phase 2 clinical trials in South Korea, the U.S., and Southeast Asia. After successfully completing Phase 1 trials in the U.S. and South Africa, the company is preparing its Investigational New Drug (IND) applications for global Phase 2 studies.

DXVX also acquired a universal COVID-19 treatment technology last year from LUCA AI Cell. DXVX stated, “Luca’s treatment technology has efficacy test data for dozens of lethal viruses, including COVID-19,” and added, “It is expected to enable the development of a new-concept COVID-19 treatment.”.

In addition to its universal COVID-19 vaccine and treatment, Dx&Vx (DXVX) is actively targeting the global pharmaceutical and biotech market through a diverse pipeline, including:

  • A next-generation mRNA vaccine platform capable of ultra-long-term storage at room temperature
  • An oral obesity treatment
  • The OVM-200 cancer vaccine based on the ROP platform technology.

In particular, the mRNA vaccine platform capable of ultra-long-term storage at room temperature is considered a game-changer, as it enables vaccination even in countries with limited cold-chain infrastructure, thereby lowering geographical barriers in responding to infectious diseases. Discussions to sign Material Transfer Agreements (MTAs) with major domestic and global mega pharmaceutical companies have recently accelerated, indicating that the platform has entered the late stages of licensing out, with visible outcomes expected within this year.

In addition, the oral obesity treatment, which is about to enter clinical trials, addresses the inconvenience of injection-based therapies while demonstrating effectiveness in improving fat metabolism, with related patents already filed. The OVM cancer vaccine represents a novel immuno-oncology approach targeting solid tumors and is also open to potential joint development with global pharmaceutical companies.

A DXVX spokesperson stated, “We are committed to advancing the development of the universal COVID-19 vaccine, while also preparing for potential future COVID-19 variants and lethal infectious diseases, such as ‘Disease X’.” The spokesperson added, “In addition to the major pipelines currently being promoted for licensing out, we are actively investing in R&D across multiple technology assets and expect sustainable long-term outcomes.”

ONEISALL MAKES ITS PROFESSIONAL GROOMING DEBUT WITH THE GRANDMASTER PRO CLIPPER

Brand’s First Pro-Grade Tool Designed for Working Groomers Who Demand Power, Precision, and Reliability

CHINO, Calif., May 29, 2025 /PRNewswire/ — After earning the trust of millions of pet parents with its popular at-home grooming tools, OneIsAll is stepping into the professional grooming arena for the first time with the launch of the Grandmaster Pro Professional Pet Clipper. Purpose-built for professional groomers and set to become the most efficient professional pet clippers on the market. This all-new clipper delivers the speed, durability, and performance required in high-volume grooming environments, without sacrificing the user-friendly design the brand is known for.

OneIsAll Grandmaster Pro 1
OneIsAll Grandmaster Pro 1

The Grandmaster Pro marks a major milestone for OneIsAll as it expands beyond the consumer space and enters the professional grooming market with a product developed specifically for working groomers. Designed in collaboration with grooming professionals, the clipper addresses key challenges of daily shop life: mat handling, grooming fatigue, battery downtime, and tool compatibility.

Key Features Tailored for Grooming Pros:

  • Up to 60% Faster Grooming Time
    High-performance blades provide ultra-smooth cutting with no snags or tugs, even on thick, curly, or matted coats, allowing groomers to complete trims in as little as 10-30 minutes per pet.
  • Nonstop Power with Swappable Battery System
    Comes with two high-capacity, rechargeable batteries and a swappable design that delivers up to 90 minutes of cordless runtime per charge.
  • Quiet, Low-Vibration Operation
    Noise and vibration-reduction technology create a calmer experience for anxious dogs while helping groomers maintain focus and control, particularly important in busy salons or mobile units.
  • Universal Blade Compatibility
    The durable steel blade reduces the need for frequent replacements and is compatible with standard blades, giving professionals the flexibility to use their preferred setup.
  • Ergonomic, Pro-Ready Build
    Lightweight, balanced design minimizes hand fatigue during long grooming sessions. Built for durability and comfort, even in high-volume shops.

“We’ve spent years perfecting grooming tools for pet parents at home, and now, we’re excited to bring that same commitment to simplicity and performance to the professional world,” said Terry Zhang, Founder and CEO of OneIsAll. “Our research revealed a significant demand and gap in the professional grooming market, highlighting key pain points for groomers. We saw an opportunity to apply our innovation and expertise to solve these challenges, leading to the development of the Grandmaster Pro. This product represents our first step into the professional grooming category, which has been engineered from the ground up to meet the needs of groomers who work with dogs all day, every day.”

The OneIsAll Grandmaster Pro Professional Pet Clipper is available now on Amazon and OneIsAll.com, starting at $129.99. The complete kit includes the clipper, two rechargeable batteries, multiple guide combs, and maintenance tools.

For more information, visit www.OneIsAll.com or follow @OneIsAll_official on social media.

About OneIsAll

OneIsAll is dedicated to “Transform How You Pet”, blending innovation with everyday practicality to improve the lives of pets and their people. From professional-grade grooming tools to smart feeding solutions and most recently tools for groomers. OneIsAll brings innovative technology and thoughtful design together to improve pet care routines worldwide. OneIsAll is proud to be honored with a CES 2025 TWICE Picks Award for their Comfy C1 Cordless Pet Grooming Vacuum Kit and sponsor the National Dog Show, celebrating the incredible bond between humans and their canine companions. Learn more at www.OneIsAll.com or follow @OneIsAll_official on Instagram and Facebook.

How clean energy fuels the comeback of Shennongjia’s golden snub-nosed monkeys?

BEIJING, May 29, 2025 /PRNewswire/ — Finding Answers in China from China.org.cn:


How clean energy fuels the comeback of Shennongjia’s golden snub-nosed monkeys?

Deep in the lush and mysterious forests of Shennongjia, central China’s Hubei province, golden figures leap effortlessly through the treetops—these are the Shennongjia golden snub-nosed monkeys. Once on the brink of extinction, they’ve made a stunning recovery and are now even recognized as a unique subspecies. But what’s the story behind their stunning revitalization? How has China’s energy transition played a key role in protecting their habitat? And can China’s ecological wisdom offer new solutions for the world?

To find out, Peruvian host Rebeca Phang from China.org.cn teams up with global energy expert Professor Saifur Rahman for a journey into the heart of Shennongjia.

When clean energy meets biodiversity conservation, and when technology empowers nature to thrive, the answers may lie in the rhythm of the forest—and in China’s commitment to green development. This is more than a story about endangered monkeys; it’s a search for a new path to harmony between humanity and nature.

How clean energy fuels the comeback of Shennongjia’s golden snub-nosed monkeys?
https://youtu.be/Wj1Hd2OaZhE

Lufax Announces Extraordinary General Meeting on June 25, 2025

SHANGHAI, May 29, 2025 /PRNewswire/ — Lufax Holding Ltd (“Lufax” or the “Company”) (NYSE: LU and HKEX: 6623), a leading financial services enabler for small business owners in China, today announced  that it will hold an extraordinary general meeting of the Company’s shareholders (the “EGM”) at 10:00 A.M. Hong Kong time on June 25, 2025 at Room 3601, No. 1333 Lujiazui Ring Road, Pudong New District, Shanghai, the People’s Republic of China, for the purposes of considering and, if thought fit, passing each of the proposed resolutions set forth in the EGM notice. The EGM notice, the EGM circular, and the form of proxy for the EGM are available on the Company’s website at https://ir.lufaxholding.com.

Holders of record of the Company’s ordinary shares on the Company’s register of members as of the close of business on May 9, 2025 (Hong Kong time) are entitled to attend the EGM in person. Holders of the Company’s American depositary shares (the “ADSs”) as of the close of business on May 9, 2025 (New York time), who wish to exercise their voting rights for the underlying ordinary shares, can submit their voting instructions to Citibank, N.A.

About Lufax

Lufax is a leading financial services enabler for small business owners in China. Lufax offers financing products designed to address the needs of small business owners and others. In doing so, Lufax has established relationships with 85 financial institutions in China as funding partners, many of which have worked with Lufax for over three years.

Investor Relations Contact

Lufax Holding Ltd
Email: Investor_Relations@lu.com 

ICR, LLC
Robin Yang
Tel: +1 (646) 308-0546
Email: lufax.ir@icrinc.com

MinIO AIStor Sets New Standard for AI and Data-Intensive Workloads with Industry-First AWS S3 Express API Support

Enterprise object storage with built-in replication brings S3 Express API performance to the entire data lakehouse, at no extra cost

REDWOOD CITY, Calif., May 29, 2025 /PRNewswire/ — MinIO, the leader in high-performance object storage for the exabyte AI era, today announced AIStor support for Amazon’s S3 Express API, a streamlined version of the general-purpose S3 API designed to deliver maximum performance for AI and data-intensive analytics workloads. MinIO AIStor is the first and only AI data storage platform to adopt Amazon’s S3 Express API and enable organizations to put all of their analytical and AI data, not just a subset, in “express mode” at no extra cost.

Introduced by AWS in 2023 and delivered via the Amazon S3 Express One Zone storage class, the Amazon S3 Express API has defined a new industry standard for high performance and developer-friendly AI and analytics storage, delivering 10x faster performance compared to the S3 Standard storage class. But, in AWS, the enhanced performance of AWS S3 Express One Zone comes at over five times the cost of S3 Standard to store data and doesn’t come with data protection and replication capabilities. Consequently, to use it safely, customers must save a durable copy of their data in S3 standard and copy data that requires high speed access into S3 Express One Zone.

With this release, MinIO is democratizing access to and use of this powerful API for all data processing needs by coupling its dramatic performance advantages with full active/passive, disaster recovery (DR), and batch replication support, all at no extra cost. Enterprises can continue leveraging the general purpose S3 API for raw source data requiring versioning and immutability before any processing, but can now leverage the high performance S3 Express API for all other downstream workloads and derived data sets, especially, but not limited to, high intensity data processing. This includes the majority of data lakehouse analytics with Apache Spark and Iceberg, AI data pre-processing, and AI model training and inference.

“Until now, use of S3 Express has typically been reserved for data that requires high speed access at the expense of enterprise features like replication and lifecycle management, due to its cost premium over S3 Standard,” said Garima Kapoor, co-founder and co-CEO, MinIO. “We’re changing that because we believe it can and should become the standard API for all analytical data and AI workloads. With the AIStor S3 Express API, pricing remains the same so enterprises can now put all of their analytical and AI data, not just a subset, in ‘express mode.’ This is drawing tremendous excitement from customers.”

“In most lakehouse environments, versioning is already handled by table formats like Apache Iceberg, which provide atomic operations at the file or table level,” said Sanjeev Mohan, principal analyst at SanjMo. “But when versioning is also enabled at the storage layer, it can create unnecessary duplication and complexity. Removing it from the storage layer simplifies the backend architecture, lowers CPU usage on storage servers, and helps prevent accidental storage growth and rising costs.”

AIStor’s S3 Express API support comes at no extra cost, without any request charges for GETs, PUTs and LISTs, and with key data protection and replication capabilities so it can be used for all enterprise analytical and AI data. Key features and benefits of the AIStor S3 Express API include:

  • Accelerated PUT and LIST operations: delivers up to 20% faster PUT operations, lowering CPU utilization, and up to 447% faster time-to-first-byte (TTFB) LIST operations relative to AIStor general purpose S3 API. This means faster training, faster analytics, and better infrastructure utilization.
  • New atomic, exclusive append operations: enables direct and safe object modification, eliminating multi-step update workflows. For example, media-broadcasting applications which add new video segments to video files can do so as they are transcoded and immediately streamed to viewers.
  • Full active/passive, disaster recovery (DR), and batch replication support: provides full performance benefits of the S3 Express API without loss of business continuity and disaster recovery (BC/DR). Synchronous replication means no data loss in the event of an outage and asynchronous replication enables data protection across the globe.
  • Streamlined and simplified API behavior: eliminates redundancies and implements simplifications and guardrails to improve the developer experience as well as application resiliency, predictability and security.

As the first and only on-premises and private cloud AI storage platform to adopt Amazon’s S3 Express API, MinIO is reinforcing its ongoing commitment to providing full and complete S3 API compatibility. To learn more about the AIStor S3 Express API, including the “how” and “why” behind specific features, please visit: https://blog.min.io/s3-express-api-added-to-aistor/. To book a demo, please visit min.io.

About MinIO
MinIO is the leader in high-performance object storage for AI. With 2B+ Docker downloads 50k+ stars on GitHub, MinIO is used by more than half of the Fortune 500 to achieve performance at scale at a fraction of the cost compared to the public cloud providers. MinIO AIStor is uniquely designed to meet the flexibility and exascale requirements of AI, empowering organizations to fully capitalize on existing AI investments and address emerging infrastructure challenges while delivering continuous business value. Founded in November 2014 by industry visionaries AB Periasamy and Garima Kapoor, MinIO is the world’s fastest growing object store.

Media Contact: Tucker Hallowell, Inkhouse, minio@inkhouse.com

NYSE Content Advisory: Pre-Market update + Nvidia, Salesforce beat on earnings

NEW YORK, May 29, 2025 /PRNewswire/ — The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today’s NYSE Pre-market update for market insights before trading begins. 

Kristen Scholer delivers the pre-market update on May 29th

  • Stocks are rising Thursday after a federal court blocked President Trump’s reciprocal tariffs. Wednesday night, the U.S. Court of International Trade ruled that President Trump exceeded his authority when he enacted the tariffs.
  • Nvidia shares popped 5% in extended trading after the company beat earnings and sales estimates. Its data center business rose 73% from a year ago.
  • Salesforce (NYSE: CRM) exceeded earnings expectations and raised its guidance after reporting results. The company said it has agreed to pay $8 billion for data management software maker Informatica.

Opening Bell
First Eagle celebrates the launch of the FEGE & FEOE ETFs

Closing Bell
Xponential Fitness (NYSE: XPOF) celebrates its 2025 Analyst & Investor Fay

Click here to download the NYSE TV App